Relating biopsy and clinical variables to radical prostatectomy findings: Can insignificant and advanced prostate cancer be predicted in a screening population?

Urology

Volumn 64, Issue 3, 2004, Pages 544-550

  Anast, Jason W ^a   Andriole, Gerald L ^a   Bismar, Tarek A ^a   Yan, Yan ^a   Humphrey, Peter A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; BIOPSY, NEEDLE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 4444232791     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.04.008     Document Type: Article

References (21)

1. American Cancer Society: Cancer Facts and Figures. American Cancer Society, Atlanta, Georgia, 2003
2. Scardino P.T., Weaver R., Hudson M.A. Early detection of prostate cancer. Hum Pathol. 23:1992;211-222
3. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 271:1994;368-374
4. Irwin M.B., Trapasso J.G. Identification of insignificant prostate cancers analysis of preoperative parameters. Urology. 44:1994;862-868
5. Terris M.K., Haney D.J., Johnstone I.M., et al. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology. 45:1995;75-80
6. Cupp M.R., Bostwick D.G., Myers R.P., et al. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol. 153:1995;1543-1548
7. Goto Y., Ohori M., Arakawa A., et al. Distinguishing clinically important from unimportant prostate cancers before treatment value of systematic biopsies. J Urol. 156:1996;1059-1063
8. Elgamal A.A., Van Poppel H.P., Van de Voorde W.M., et al. Impalpable invisible stage T1c prostate cancer characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol. 157:1997;244-250
9. Carter H.B., Sauvageot J., Walsh P.C., et al. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol. 157:1997;2206-2209
10. Epstein J.I., Chan D.W., Sokoll L.J., et al. Nonpalpable stage T1c prostate cancer prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 160:1998;2407-2411
11. Noguchi M., Stamey T.A., McNeal J.E., et al. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol. 166:2001;104-110
12. Augustin H., Hammerer P.G., Graefen M., et al. Insignificant prostate cancer in radical prostatectomy specimen time trends and preoperative prediction. Eur Urol. 43:2003;455-460
13. Smith D.S., Catalona W.J. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol. 152:1994;1732-1736
14. Bismar T.A., Lewis J.S. Jr, Vollmer R.T., et al. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol. 27:2003;432-440
15. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324:1991;1156-1161
16. Lewis J.S. Jr, Vollmer R.T., Humphrey P.A. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol. 118:2002;442-450
17. Humphrey P.A., Keetch D.W., Smith D.S., et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol. 155:1996;816-820
18. Carter H.B., Walsh P.C., Landis P., et al. Expectant management of nonpalpable prostate cancer with curative intent preliminary results. J Urol. 167:2002;1231-1234
19. Naughton C.K., Smith D.S., Humphrey P.A., et al. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores a retrospective study. Urology. 52:1998;808-813
20. Zlotta A.R., Remzi M., Snow P.B., et al. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less. J Urol. 169:2003;1724-1728
21. Best C.J., Leiva I.M., Chuaqui R.F., et al. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol. 12:2003;63-70